TTA-A8

TTA-A8 (Compound 13) is a short-acting T-type calcium channel antagonist with oral activity, exhibiting an IC50 value of 31.3 nM in the FLIPR depolarization assay. TTA-A8 possesses favorable pharmacokinetic properties, making it suitable for research on epilepsy and sleep[1].

Product Specifications

CAS Number

[1146395-46-1]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Calcium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/tta-a8.html

Solubility

10 mM in DMSO

Smiles

CC1=NC=CN=C1C2=CC=C(C=C2)CC(N[C@@H](C3=CC=C(C=N3)OCC(F)(F)F)C)=O

Molecular Formula

C22H21F3N4O2

Molecular Weight

430.42

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

References & Citations

[1]Yang Z Q, et al. Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents[J]. ACS Medicinal Chemistry Letters, 2010, 1 (9) : 504-509.